Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649324 · ClinicalTrials.gov registry record · Early Phase 1
Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg
A Early Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
NCT00649324 is a Early Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00649324, a Early Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's hydrochlorothiazide 50 mg tablets to Ivax's Hydrochlorothiazide 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.
Interventions
- DRUG Hydrochlorothiazide Tablets 50 mg
- DRUG Hydrochlorothiazide Tablets (50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-10 |
| Est. Completion | 2005-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00649324
The ClinicalTrials.gov registry entry for NCT00649324 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydrochlorothiazide Tablets 50 mg is the first listed.
NCT00649324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00649324 about?
NCT00649324 is a clinical study titled "Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg". The objective of this study was to investigate the bioequivalence of Mylan's hydrochlorothiazide 50 mg tablets to Ivax's Hydrochlorothiazide 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.
What is the current status of trial NCT00649324?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2005-10. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00649324?
The interventions under investigation include: Hydrochlorothiazide Tablets 50 mg (DRUG), Hydrochlorothiazide Tablets (50 mg (DRUG).
Who is sponsoring clinical trial NCT00649324?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.